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Abstract: The dysfunction of astrocytic inwardly rectifying potassium (Kir) 4.1 channels, which
mediate the spatial potassium-buffering function of astrocytes, is known to be involved in the
development of epilepsy. Here, we analyzed the Kir4.1 expressional changes in Leucine-Rich
Glioma-Inactivated 1 (Lgi1) mutant rats, which is a model of autosomal dominant lateral temporal lobe
epilepsy in humans, to clarify the role of astrocytic Kir4.1 channels in Lgi1-related epileptogenesis.
Priming acoustic stimulation (at postnatal day 16) conferred seizure susceptibility on Lgi1 mutant rats,
which evoked audiogenic seizures with test stimulation at eight weeks. In the seizure-susceptible
Lgi1 mutant rats (before test stimulation), astrocytic Kir4.1 expression was down-regulated
region-specifically in the cerebral cortex, hippocampus, and amygdala. In addition, prophylactic
treatments of Lgi1 mutant rats with valproic acid (VPA, 30 mg/kg and 200 mg/kg) for two
weeks prevented both the development of seizure susceptibility and the down-regulation of Kir4.1
expression in astrocytes. The present study demonstrated for the first time that the astrocytic Kir4.1
expression was reduced in the Lgi1-related seizure model, suggesting that the down-regulation of
Kir4.1 channels in astrocytes is involved in audiogenic epileptogenesis caused by Lgi1 mutation.
In addition, VPA seemed to have a prophylactic effect on Lgi1-related seizures.
Keywords: astrocytes; epilepsy; Kir4.1 channels; Lgi1; ADLTE; antiepileptics; valproic acid
1. Introduction
Astrocytes are a major component of glial cells in the brain that form tripartite synapses in
conjunction with neuronal components (presynaptic nerve terminal and postsynaptic neuronal
membrane), and actively regulate the excitability and plasticity of neurons. They maintain extracellular
ion homeostasis, metabolize neurotransmitters (e.g., glutamate and GABA), and secrete various
neuroactive substances (e.g., gliotransmitters, neurotrophic factors, and cytokines) [1–3]. Specifically,
the spatial potassium (K+) buffering by astrocytes’ functions is a clearance mechanism of excessive
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extracellular K+ secreted from excited neurons, and is essential for controlling neuronal excitability.
If astrocytic K+ buffering is disrupted, it increases the extracellular levels of K+ and glutamate at the
synapses, and causes the abnormal excitation of neurons [4–7].
Spatial K+ buffering currents in astrocytes are primarily conducted by the inwardly rectifying
K+ (Kir) channels containing Kir4.1 subunits (Kir4.1 channels), which consist of Kir4.1 homotetramer
and Kir4.1/5.1 heterotetramer channels [7,8]. Previous studies using conditional knockout mice have
shown that the specific deletion of Kir4.1 in astrocytes depolarized their resting membrane potential
and markedly reduced the transport capacity of K+ and glutamate into astrocytes, causing ataxia,
epileptic symptoms, and early mortality [9]. These findings suggest that disruption of the spatial K+
buffering function of astrocytes is associated with the induction of motor disorders, including epilepsy.
In fact, loss-of-function mutations in the human KCNJ10 gene encoding Kir4.1 were reported to cause
the epileptic disorders known as “EAST” (Epilepsy, Ataxia, Sensorineural deafness, and Tubulopathy)
or “SeSAME” (Seizures, Sensorineural deafness, Ataxia, Mental retardation, and Electrolyte imbalance)
syndrome [10–12]. In addition, astrocytic Kir4.1 expression was known to be reduced (down-regulated)
in some brain regions (e.g., hippocampus and amygdala) in rodent epilepsy models [13,14], and in
seizure focus specimens from temporal lobe epilepsy (TLE) patients [15–17], suggesting that the
reduced activity of the Kir4.1 channels evokes seizures. Furthermore, we previously showed that
the inhibition (knockdown or blockade) of Kir4.1 channels facilitated the expression of brain-derived
neurotrophic factor (BDNF) in astrocytes, which has long been implicated in the development of
epilepsy (epileptogenesis) [18,19]. Interestingly, repeated treatments with antiepileptic drugs such as
valproic acid (VPA) were found to up-regulate (elevate) the expression of astrocytic Kir4.1 channels in
the limbic regions (e.g., amygdala and hippocampus) [20]. Therefore, astrocytic Kir4.1 channels seem
to closely participate in the pathogenesis and treatment of epilepsy both in animals and in patients.
Autosomal dominant lateral temporal lobe epilepsy (ADLTE, OMIM 600512) is an epilepsy
disorder with characteristic manifestations such as auditory auras and seizures triggered by auditory
stimuli. ADLTE was reported to be caused by several heterozygous mutations of leucine-rich
glioma-inactivated 1 (LGI1) [21,22]. Moreover, the secreted synaptic protein Lgi1 has been shown
to regulate the function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type
glutamate receptors and potassium channels (e.g., Kv1.1 channels) by forming complexes with a
disintegrin and metalloproteinase protein 22 (ADAM22) and ADAM23, which are members of the
membrane-anchored protein family [23–26]. However, the pathophysiological mechanisms underlying
Lgi1-related epileptogenesis remain unknown.
We previously developed a novel rat model of Lgi1-related seizures that carries a missense
mutation (L385R) of the Lgi1 gene [27]. The Lgi1 mutant rats showed audiogenic seizure susceptibility,
resembling the clinical features of ADLTE [27,28]. In the present study, we evaluated the Kir4.1
expressional changes in astrocytes during the development of audiogenic epilepsy in Lgi1 mutant
rats to clarify the potential involvement of astrocytic Kir4.1 channels in Lgi1-related epileptogenesis.
Moreover, we also studied the prophylactic actions of VPA in Lgi1-related epileptogenesis, with a
focus on its regulation of Kir4.1 channel expression.
2. Results
2.1. Audiogenic Seizure Induction
Wild-type (WT) rats and Lgi1 mutant rats were divided into four groups. Groups A and B did not
receive the acoustic priming stimulation without (Group A) and with (Group B) the test stimulation
(130 dB, 10 kHz, one minute) at the age of eight weeks, respectively (Figure 1). Groups C and D
received the acoustic priming stimulation (130 dB, 10 kHz, five minutes) at postnatal day (P) 16
without (Group C) and with (Group D) the test stimulation at eight weeks, respectively.
In all of the non-primed Group B animals (either WT or Lgi1 mutant rats), the acoustic test
stimulation at eight weeks did not cause any behavioral changes (Table 1). In contrast, in all of the
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primed Group D animals (either WT or Lgi1 mutant rats), the acoustic test stimulation at eight weeks
evoked wild running behavior. Moreover, Lgi1 mutant rats (n = 8), except for one, showed generalized
tonic–clonic seizures (GTCSs) following wild running, although none of the WT rats in Group D
exhibited GTCSs (Table 1).
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Figure 1. Audiogenic seizure induction. Wild-type rats and leucine-rich glioma-inactivated 1 (Lgi1) 
mutant rats were divided into four groups: Group A (no acoustic stimulation), Group B (only test 
stimulation), Group C (only priming stimulation), and Group D (both priming and test stimulation).  
Table 1. The responses to acoustic test stimulation at eight weeks in wild-type rats and Lgi1 mutant 
rats. WR: wild running; GTCS: generalized tonic–clonic seizure. 
Genotype 
Acoustic Stimulation Responses to Test Stimulation (No. of Animals) 
Priming Test Total None WR WR+ GTCS 
Group B  
Wild type 
- + 6 6 0 0 
Group B  
Lgi1-mutant 
- + 7 7 0 0 
Group D 
Wild type 
+ + 8 0 8 0 
Group D 
Lgi1-mutant 
+ + 8 0 1 7 (88%) 
2.2. Expressional Changes in Astrocytic Kir4.1 during Audiogenic Epileptogenesis 
We first confirmed the expression pattern of Kir4.1 in WT F344 rats using the immunofluorescent 
double-staining techniques. As in other strains (Wistar and SD rats) [14,20,29], Kir4.1-
immunoreactivity (IR) was mostly co-stained with glial fibrillary acidic protein (GFAP), which is a 
specific marker for astrocytes, in stellate-shaped cells (Figure 2A top), illustrating that Kir4.1 channels 
are specifically expressed in astrocytes in F344 rats. In addition, Kir4.1 expression in astrocytes was 
considerably reduced in the Lgi1 mutant rats that received priming stimulation at P16 (Figure 2A 
bottom). 
Figure 1. Audiogenic seizure induction. ild-type rats and leucine-rich glio a-inactivated 1 (Lgi1)
utant rats were divided into four groups: Group A (no acoustic sti ulation), Group B (only test
stimulation), Group C (only priming stimulation), and Group D (both priming and test stimulation).
Table 1. The responses to acoustic test stimulation at eight weeks in wild-type rats and Lgi1 mutant
rats. WR: wild running; GTCS: generalized tonic–clonic seizure.
Genotype
Acoustic Stimulation Responses to Test Stimulation (No. of Animals)
Priming Test Total None WR WR+ GTCS
Group B
Wild type - + 6 6 0 0
Group B
Lgi1-mutant - + 7 7 0 0
Group D
Wild type + 8 0 8 0
Group D
Lgi1-mutant + 8 0 1 7 (88%)
2.2. Expressional Changes in Astrocytic Kir4.1 during Audiogenic Epileptogenesis
e first confirmed the expression pattern of Kir4.1 in T F344 rats using the i unofluorescent
double-staining techniques. As in other strains (Wistar and SD rats) [14,20,29], Kir4.1-immunoreactivity
(IR) was mostly co-stained with glial fibrillary acidic protein (GFAP), which is a specific marker for
astrocytes, in stellate-shaped cells (Figure 2A top), illustrating that Kir4.1 channels are specifically
expressed in astrocytes in F344 rats. In addition, Kir4.1 expression in astrocytes was considerably
reduced in the Lgi1 mutant rats that received priming stimulation at P16 (Figure 2A bottom).
Int. J. Mol. Sci. 2019, 20, 1013 4 of 15
Int. J. Mol. Sci. 2019, 20, x; doi: www.mdpi.com/journal/ijms 
 
Figure 2. Kir4.1 expression in astrocytes. (A) Representative images of immunofluorescence double 
staining for glial fibrillary acidic protein (GFAP) and Kir4.1 in the hippocampal CA1 region in wild-
type F344 rats (top panels) and Lgi1 mutant rats (bottom panels). Scale bar: 100 μm. (B) Schematic 
illustration of a brain section (Bregma -3.48 mm level) selected for quantitative analysis of 
immunoreactivity (IR) of Kir4.1 or GFAP. Squares in each brain region indicate the areas analyzed for 
counting of Kir4.1-IR-positive or GFAP-IR-positive cells. Medial parietal association cortex (MPtA), 
primary somatosensory cortex barrel field (S1BF), primary auditory cortex (Au1), perirhinal cortex 
(PRh), piriform cortex (Pir), hippocampal CA1, CA2, CA3, and dentate gyrus (DG), medial 
amygdaloid nucleus posteroventral part (MePV), medial amygdaloid nucleus posterodorsal part 
(MePD), posteromedial cortical amygdaloid nucleus (PMCo), basomedial amygdaloid nucleus 
posterior part (BMP), basolateral amygdaloid nucleus posterior part (BLP), lateral amygdaloid 
nucleus ventromedial part (LaVM), lateral habenula (LHb), ventromedial thalamus (VM), posterior 
hypothalamus (PH), dorsomedial hypothalamic nucleus, and dorsal part (DMD). (C) Representative 
images of immunohistochemical staining for GFAP and Kir4.1 in the hippocampal CA1 regions of 
non-primed wild type rats (upper left panels), primed wild type rats (lower left panels), non-primed 
Lgi1 mutant rats (upper right panels), and primed Lgi1 mutant rats (lower right panels) after 
audiogenic seizure induction. Scale bar: 100 μm. 
Topographical mapping analysis for the changes in Kir4.1 and GFAP expression was performed 
by counting the number of Kir4.1-IR-positive and GFAP-IR-positive cells stained by the avidin-biotin 
complex (ABC) method. Nineteen brain regions were analyzed, including the cerebral cortex, 
hippocampus, amygdala, thalamus, and hypothalamus, which were reported to be activated with 
audiogenic seizures in Lgi1 mutant rats [28] (Figure 2B). Kir4.1-IR was mostly expressed in stellate-
shaped cells, and there was no morphological difference in Kir4.1-IR or GFAP-IR positive cells 
between WT and Lgi1 mutant rats (Figure 2C).  
Neither priming stimulation at P16 nor test stimulation at eight weeks affected the number of 
astrocytes (GFAP-IR-positive cells) per se either in WT or Lgi1 mutant rats of groups A–D (Figure 3).  
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(B) Schematic illustration of a brain section (Bregma −3.48 mm level) selected for quantitative
analysis of immunoreactivity (IR) of Kir4.1 or GFAP. Squares in each brain region indic te the areas
analyzed for counting of Kir4.1-IR-positive or GFAP-IR-positive cells. Medial parietal association
cortex (MPtA), primary somatosensory cortex barrel field (S1BF), primary auditory cortex (Au1),
perirhinal cortex (PRh), piriform cortex (Pir), hippocampal 1, CA2, CA3, and dentate gyrus (DG),
medial amygdaloid nucleus posteroventral part (MePV), medial amygdaloid nucleus posterodorsal
part (MePD), posteromedial cortical amygdaloid nucleus (PMCo), basomedial a ygdaloid nucleus
posterior part (B P), basolateral a ygdaloid nucleus posterior part (BLP), lateral a ygdaloid
nucleus ventromedial part (LaV ), lateral habenula (LHb), ventromedial thalamus (V ), posterior
hypothalamus (PH), dorsomedial hypothalamic nucleus, and dorsal part (DMD). (C) Representative
images of immunohistochemical staining for GFAP and Kir4.1 in the hippocampal CA1 regions of
non-primed wild type rats (upper left panels), primed wild type rats (lower left panels), non-primed
Lgi1 mutant rats (upper right panels), and primed Lgi1 mutant rats (lower right panels) after audiogenic
seizure induction. Scale bar: 100 µm.
Topographical mapping analysis for the changes in Kir4.1 and GFAP expression was performed
by counting the number of Kir4.1-IR-positive and GFAP-IR-positive cells stained by the avidin-biotin
complex (ABC) method. Nineteen brain regions were analyzed, including the cerebral cortex,
hippocampus, amygdala, thalamus, and hypothalamus, which were reported to be activated
with audiogenic seizures in Lgi1 mutant rats [28] (Figure 2B). Kir4.1-IR was mostly expressed in
stellate-shaped cells, and there was no morphological difference in Kir4.1-IR or GFAP-IR positive cells
between WT and Lgi1 mutant rats (Figure 2C).
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Neither priming stimulation at P16 nor test stimulation at eight weeks affected the number of
astrocytes (GFAP-IR-positive cells) per se either in WT or Lgi1 mutant rats of groups A–D (Figure 3).Int. J. Mol. Sci. 2019, 20, x; doi: www.mdpi.com/journal/ijms 
 
Figure 3. Changes in the number of GFAP-immunoreactivity (IR)-positive cells after development of 
audiogenic epilepsy. The GFAP-IR-positive cells in each group of wild-type rats (A–D) and Lgi1 
mutant rats are shown in each region of the cortex (A), hippocampus (B), and amygdala (C). Each 
point represents the mean ± S.E.M. of six to eight animals. 
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stimulation in Lgi1 mutant rats (Group C) (Figures 2C and 4). The Kir4.1 expression rate (ratio of 
Kir4.1-IR-positive cells versus GFAP-IR-positive cells) in the primed Lgi1 mutant rats was also 
significantly decreased by the priming stimulation in the cerebral cortex (Medial parietal association 
cortex, MPtA; primary auditory cortex, Au1; perirhinal cortex, PRh; and piriform cortex, Pir), 
hippocampus (CA1, CA2, and CA3), and amygdala (medial amygdaloid nucleus posteroventral part, 
MePV; medial amygdaloid nucleus posterodorsal part, MePD; posteromedial cortical amygdaloid 
nucleus, PMCo; and basomedial amygdaloid nucleus posterior part, BMP) (Figure 5). These changes 
in Kir4.1 expression seemed to be time-dependent, since there was no acute change in Kir4.1 
expression in Lgi1 mutant rats at one day after priming stimulation (P17) (Supplementary Figure S1). 
Although adiogenic seizures induced by the test stimulation tended to further reduce Kir4.1 
expression in some brain regions (e.g., cerebral cortex, hippocampus, and amygdala) of the Lgi1 
mutant rats, these changes between Group C and Group D were not statistically significant (figures 
4 and 5). We also checked the changes in Kir4.1 expression by three-way (i. mutation; ii. priming 
stimulation; iii. test stimulation) ANOVA, which revealed a statistical significance with the two 
factors, mutation and priming stimulation, but not with the test stimulation, in most brain regions. 
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o ever, the number of Kir4.1-IR-positive cells was markedly reduced by the priming stimulation
in Lgi1 mutant rats (Group C) (Figures 2C and 4). The Kir4.1 expression rate (ratio of Kir4.1-IR-positive
cells versus GFAP-IR-positive cells) in the primed Lgi1 mutant rats was also significantly decreased
by the priming stimulation in the cerebral cortex (Medial parietal association cortex, MPtA; primary
auditory cortex, Au1; perirhinal cortex, PRh; and piriform cortex, Pir), hippocampus (CA1, CA2, and
CA3), and amygdala (medial amygdaloid nucleus posteroventral part, MePV; medial amygdaloid
nucleus posterodorsal part, MePD; posteromedial cortical amygdaloid nucleus, PMCo; and basomedial
amygdaloid nucleus posterior part, BMP) (Figure 5). These changes in Kir4.1 expression seemed to be
time-dependent, since there was no acute change in Kir4.1 expression in Lgi1 mutant rats at one day
after priming stimulation (P17) (Supplementary Figure S1). Although adiogenic seizures induced by
the test stimulation tended to further reduce Kir4.1 expression in some brain regions (e.g., cerebral
cortex, hippocampus, and amygdala) of the Lgi1 mutant rats, these changes between Group C and
Group D were not statistically significant (Figures 4 and 5). We also checked the changes in Kir4.1
expression by three-way (i. mutation; ii. priming stimulation; iii. test stimulation) ANOVA, which
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revealed a statistical significance with the two factors, mutation and priming stimulation, but not with
the test stimulation, in most brain regions.Int. J. Mol. Sci. 2019, 20, x; doi: www.mdpi.com/journal/ijms 
 
Figure 4. Changes in the number of Kir4.1-immunoreactivity (IR)-positive cells after development of 
audiogenic epilepsy. Kir4.1-IR-positive cells in each group of wild-type rats (A–D) and Lgi1 mutant 
rats are shown in each region of the cortex (A), hippocampus (B), and amygdala (C). Each point 
represents the mean ± S.E.M. of six to eight animals. * p < 0.05, ** p < 0.01, significantly different from 
Group A of wild-type rats and Lgi1 mutant rats. † p < 0.05, †† p < 0.01, significantly different from 
Group B of wild-type rats and Lgi1 mutant rats. 
i ic epilepsy. Kir4.1-IR-posit ve cells in each group of wild-type rats (A–D) and Lgi1 mutant r ts
are shown in each r gion of the cortex (A), hippocam us (B), and amygdala (C). Each point represents
the mean ± S.E.M. of six to eight animals. * p < 0.05, * p < 0.01, significantly different from Group A
of wild-type rats and Lgi1 mutant rats. † p < 0.05, † p < 0.01, significantly differe t from G oup B of
wild-type rats and Lgi1 mutant rats.
In contrast to Lgi1 mutant rats, WT rats showed no changes in Kir4.1 expression with or without
the priming stimulation at P16 and the test stimulation at eight weeks in all of the examined brain
regions (Figures 4 and 5).
Int. J. Mol. Sci. 2019, 20, 1013 7 of 15
Int. J. Mol. Sci. 2019, 20, x; doi: www.mdpi.com/journal/ijms 
 
Figure 5. Changes in astrocytic Kir4.1 expression after the development of audiogenic epilepsy. The 
Kir4.1 expression rate in each group of wild-type rats (A–D) and Lgi1 mutant rats are shown in each 
region of the cortex (A), hippocampus (B), and amygdala (C). The Kir4.1 expression rate was 
expressed as the ration of Kir4.1-immunoreactivity (IR)-positive cells to GFAP-IR-positive cells in 
each region by staining a pair of successive brain sections with anti-Kir4.1 or anti-GFAP antibodies. 
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2.3. Prophylactic Actions of VPA on Seizure Susceptibility in Lgi1 Mutant Rats 
We next examined the prophylactic effects of VPA on the audiogenic seizure susceptibility in 
Lgi1 mutant rats. Lgi1 mutant rats were treated with VPA (30 and 200 mg/kg, i.p.) for two weeks from 
one day before priming stimulation. Under these conditions, both 30 mg/kg and 200 mg/kg of VPA 
effectively prevented GTCS induction (Figure 6 and Table 2). Only one out of five Lgi1 mutant rats 
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Group A of wild-type rats and Lgi1 mutant rats. † p < 0.05, †† p < 0.01, significantly different from
Group B of wild-type rats and Lgi1 mutant rats.
2.3. Prophylactic Actions of VPA on Seizure Susceptibility in Lgi1 Mutant Rats
We next examined the prophylac ic effect of VPA the audiogenic seizure susceptibil ty in Lgi1
muta t rats. Lgi1 mutant rats were treated with VPA (30 and 200 mg/kg, i.p.) for two weeks from
one day before priming stimulation. Under these conditions, both 30 mg/kg and 200 mg/kg of VPA
effectively prevented GTCS induction (Fig re 6 and Table 2). Only one out of five Lgi1 mutant rats
(20%) exhibited GTCSs with test stimulation, whereas three out of four Lgi1 mutant rats (75%) treated
with saline showed GTCSs.
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Table 2. The responses to acoustic test stimulation at eight weeks in wild-type rats and Lgi1 mutant 
rats treated with VPA. WR: wild running; GTCS: generalized tonic–clonic seizure. 
Genotype Drug (mg/kg) 
Responses to Test Stimulation (No. of Animals) 
Total None WR WR + GTCS 
Wild type Saline 6 0 6 0 
Wild type VPA 200 6 0 4 0 
Lgi1-mutant Saline 4 0 1 3 (75%) 
Lgi1-mutant VPA 30 5 0 4 1 (20%) 
Lgi1-mutant VPA 200 5 0 4 1 (20%) 
2.4. Expressional Changes in Astrocytic Kir4.1 with Treatment of VPA 
Similar to the results of prior experiments, the Kir4.1 expression rate significantly decreased in 
the cerebral cortex (Au1 and Pir), hippocampus (CA1, CA2, and DG), and amygdala (BMP) in the 
primed Lgi1 mutant rats treated with saline (Figure 7). However, the prophylactic treatment with 
VPA (30 mg/kg and 200 mg/kg, i.p.) for two weeks significantly elevated the Kir4.1 expression rate 
in a dose-related manner in the cerebral cortex (Pir), hippocampus (CA1 and CA2), and amygdala 
(BMP) (Figure 7). 
Figure 6. Prophylactic effects of valproic acid (VPA) on audiogenic seizure susceptibility. Animals
were intraperitoneally injected with VPA (30 mg/kg and 20 mg/kg) or saline for 14 continuous days
from P15 (one day before priming stimulation).
Table 2. The responses to acoustic test stimulation at eight weeks in wild-type rats and Lgi1 mutant
rats treated with VPA. WR: wild running; GTCS: generalized tonic–clonic seizure.
Genotype Drug (mg/kg)
Responses to Test Stimulation (No. of Animals)
Total None WR WR + GTCS
Wild type Saline 6 0 6 0
Wild type VPA 200 6 0
Lgi1-mutant Saline 4 0 1 3 (75%)
Lgi1-mutant VPA 30 5 0 4 1 (20%)
Lgi1-mutant VPA 200 5 0 4 1 (20%)
2.4. Expressional Changes in Astrocytic Kir4.1 with Treatment of VPA
Similar to the results of prior experiments, the Kir4.1 expression rate significantly decreased in
the cerebral cortex (Au1 and Pir), hippocampus (CA1, CA2, and DG), and amygdala (BMP) in the
primed Lgi1 mutant rats treated with saline (Figure 7). However, the prophylactic treatment with VPA
(30 mg/kg and 200 mg/kg, i.p.) for two weeks significantly elevated the Kir4.1 expression rate in a
dose-related manner in the cerebral cortex (Pir), hippocampus (CA1 and CA2), and amygdala (BMP)
(Figure 7).
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Figure 7. Expression changes in astrocytic Kir4.1 with treatment of valproic acid (VPA). Kir4.1 
expression ratios of wild-type rats treated with saline and Lgi1 mutant rats treated with saline or VPA 
(30 mg/kg or 200 mg/kg) are shown in each region of the cortex (A), hippocampus, and amygdala (B). 
The Kir4.1 expression rate was expressed as the ratio of Kir4.1-IR-positive cells to GFAP-IR-positive 
cells in each region. Each point represents the mean ± S.E.M. of four to six animals. * p < 0.05, ** p < 
0.01, significantly different from wild-type rats treated with saline. † p < 0.05, significantly different 
from Lgi1 mutant rats treated with saline. 
3. Discussion 
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epileptic disorders including not only epilepsy models in animals [13,14], but also EAST/SeSAME 
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mental retardation 1 (Fmr1) knockout mice [31]. It should be noted that the down-regulation of 
astrocytic Kir4.1 in Lgi1 mutant rats was obtained without any seizure experience (before applying 
acoustic test stimulation) after the development of audiogenic epileptogenesis. The present results 
suggested that the reduced expression of astrocytic Kir4.1 expression is involved in Lgi1-related 
epileptic disorders. The dysfunction of astrocytic Kir4.1 channels elevates the extracellular levels and 
K+ and glutamate by suppressing the special K+ buffering function of astrocytes, which increases the 
excitability of neurons [4–7]. In addition, we previously showed that down-regulation of the Kir4.1 
channel expression enhanced the expression of BDNF, which is a key modulator of epileptogenesis, 
in astrocytes [18,19]. Knockdown of the BDNF gene [32–35] or inhibition of the BDNF receptor TrkB 
[36,37] has been shown to suppress seizure development. Thus, it seems possible that the down-
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3. Discussion
It has been shown that the hypofunction of Kir4.1 channels in astrocytes was involved in various
epileptic disorders including not only epilepsy models in animals [13,14], but also EAST/SeSA E
syndrome with KCNJ10 mutations [10–12] and TLE in humans [15–17]. Here, we demonstrated for the
first time that astrocytic Kir4.1 expression was markedly reduced in the cerebral cortex, hippocampus,
and amygdala during the audiogenic epileptogenesis in Lgi1 mutant rats, which is a rat model of human
ADLTE. The brain regions, which showed a down-regulation of Kir4.1 expression, were consistent
with the regional distribution of Lgi1 expression [30]. The hippocampus and amygdala were also
suggested to be involved in generation of audiogenic seizures in Fragile X mental retardation 1 (Fmr1)
knockout mice [31]. It should be noted that the down-regulation of astrocytic Kir4.1 in Lgi1 mutant
rats was obtained without any seizure experience (before applying acoustic test stimulation) after the
development of audiogenic epileptogenesis. The present results suggested that the reduced expression
of astrocytic Kir4.1 expression is involved in Lgi1-related epileptic disorders. The dysfunction of
astrocytic Kir4.1 channels elevates the extracellular levels and K+ and glutamate by suppressing
the special K+ buffering function of astrocytes, which increases the excitability of neurons [4–7].
In addition, we previously showed that down-regulation of the Kir4.1 channel expression enhanced
the expression of BDNF, which is a key modulator of epileptogenesis, in astrocytes [18,19]. Knockdown
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of the BDNF gene [32–35] or inhibition of the BDNF receptor TrkB [36,37] has been shown to suppress
seizure development. Thus, it seems possible that the down-regulation of astrocytic Kir4.1 channels
participates in the development of epilepsy in Lgi1 mutant rats.
Epileptogenesis generally shows a time lag until the development of seizures following trigger
events (e.g., stroke, traumatic brain injury, and status epilepticus) [38]. In audiogenic epileptogenesis
caused by Lgi1 mutation, astrocytic Kir4.1 expression also required time to be down-regulated.
Although the mechanisms underlying the down-regulation of Kir4.1 expression by Lgi1 mutation are
still uncertain, it has been recently demonstrated that Kir4.1 channel expression in astrocytes was
down-regulated by increased glutamate signaling [39]. Since previous studies have suggested that
the synaptic release of glutamate is increased by Lgi1 mutation [40,41], this might be involved in the
down-regulation of astrocytic Kir4.1 expression in Lgi1 mutant rats. In addition, Lgi1 is known to
regulate the expression and/or clustering of potassium channels (e.g., Kv1.1 channels) through the
interaction with the membrane-anchored proteins (ADAM22 and ADAM23) [23,26]. Thus, disruptions
of the Lgi1–ADAM22/23 interaction in Lgi1 mutant rats might also influence the Kir4.1 channel
expression in astrocytes. Further studies are required to clarify the mechanisms underlying the
interaction of Lgi1 with Kir4.1 channels in the Lgi1-related epileptogenesis.
VPA is widely used as an antiepileptic drug that is effective for both generalized and partial
seizures. It enhances GABAergic neurotransmission by inhibiting the GABA metabolic enzyme, GABA
transaminase [19,42]. In addition, VPA also blocks voltage-gated sodium channels and T-type calcium
channels. These actions are considered to cause neuronal inhibition and contribute to its anticonvulsive
activity. Nonetheless, several studies have suggested that VPA shows prophylactic effects on seizure
generation and might have the potential to prevent epileptogenesis [43–45]. In consistent with this
possibility, we have previously shown that repeated treatment of animals with VPA enhanced astrocytic
Kir4.1 expression in the cerebral cortex and limbic regions (hippocampus and amygdala), which
seems to inhibit epileptogenesis via facilitating the spatial potassium buffering function of astrocytes.
In the present study, we confirmed that VPA could alleviate the epileptogenesis in Lgi1 mutant rats
with elevating astrocytic Kir4.1 expression. Our results suggest that VPA can prevent or alleviate
Lgi1-related epileptogenesis by normalizing the down-regulation of the astrocytic Kir4.1 channel.
In conclusion, we analyzed the astrocytic Kir4.1 expression during audiogenic epileptogenesis in
Lgi1 mutant rats. Kir4.1 expression in astrocytes was significantly decreased by the postnatal priming
stimulation in the cerebral cortex, hippocampus, and amygdala. In addition, prophylactic treatments
with VPA effectively alleviated audiogenic seizure susceptibility and prevented the reduced expression
of astrocytic Kir4.1 channels in Lgi1 mutant rats. The present study suggests that the down-regulation
of Kir4.1 channels in astrocytes is involved in audiogenic seizure generation caused by Lgi1 mutation.
Moreover, VPA seemed to have a prophylactic effect on Lgi1-related epileptogenesis. However, this
study evaluated the Kir4.1 levels solely by counting IR-positive cells, but not by calculating the IR
area [46], so that compensatory changes represented by increased Kir4.1-IR in the remaining positive
cells could not be excluded. Further analyses of Kir4.1 expression at cellular and subcellular levels are
necessary to delineate the mechanisms underlying the Kir4.1 down-regulation by Lgi1 mutation and
its relationship to epileptogenesis.
4. Materials and Methods
4.1. Animals
F344-Lgi1m1Kyo rats (NBRP Rat No. 0656), carrying a heterozygous missense mutation (L385R/+)
generated by N-ethyl-N-nitrosourea (ENU) mutagenesis [27], were obtained from the National
BioResource Project-Rat (NBRP-Rat, http://www.anim.med.kyoto-u.ac.jp). The housing conditions of
the rats and animal care methods complied with the Guide for the Care and Use of Laboratory Animals
of the Ministry of Education, Science, Sports and Culture of Japan. The experimental procedures used
were approved by the Animal Research Committee of Kyoto University (Med Kyo 14560, 6 November
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2014) and Osaka University of Pharmaceutical Sciences (No.15, 30 March 2015). Only male rats were
used for phenotypic analyses.
4.2. Genotyping
F344-Lgi1m1Kyo rats were mated with their wild-type littermates. The blood samples of rat pups at
P15 were used for genotyping using a PCR restriction fragment length polymorphism (RFLP) technique.
Briefly, exon 8 of Lgi1, including the mutation site, was amplified by PCR with primers (forward:
5′-CCACACATCTAATGTCTCATCTGTT-3′, reverse: 5′-AGGATCAAATGAGGTGTTCTGAG-3′) using
the Ampdirect Plus PCR buffer (Shimadzu, Kyoto, Japan). The PCR products were digested with Xsp I
(Takara Bio, Shiga, Japan); then, fragments (mutant allele: 399 bp, wild allele: 350 bp) were separated
by conventional agarose gel electrophoresis.
4.3. Audiogenic Seizure Induction
Animals divided into four groups (Group A–D) were individually exposed to auditory stimulation
using a previously reported method [27,28] (Figure 1). Priming stimulation was performed in P16 rats
with a sound stimulus (130 dB, 10 kHz, five minutes). Test stimulation was performed with a sound
stimulus (130 dB, 10 kHz, one minute) at eight weeks. Within two hours after seizure induction
or a sham procedure, the animals were deeply anesthetized with pentobarbital (80 mg/kg, i.p.)
that was transcardially perfused with ice-cold phosphate-buffered saline (PBS), and then with 4%
paraformaldehyde solution. The brains were removed from the skull and placed in fresh fixative
for 24 h.
4.4. Immunofluorescence Staining
Immunofluorescence double staining of Kir4.1 with GFAP (a specific marker for astrocytes)
was performed as published previously [14,20,29]. Briefly, fixed brain samples were embedded in
paraffin and cut into four-µm thick sections. Sections were autoclaved for 20 min to retrieve the
antigen, and blocked with 1% bovine serum albumin (BSA) for 30 min. The sections were incubated
with primary antibodies for GFAP (mouse monoclonal, 1:50; Progen, Heidelberg, Germany) and
Kir4.1 (rabbit polyclonal, 1:100; Alomone Labs, Jerusalem, Israel) at 4 ◦C overnight. Subsequently,
secondary antibodies of tetramethylrhodamine-5- (and 6)-isothiocyanate (TRITC; red fluorescence)
goat anti-mouse (1:50; Sigma-Aldrich, St. Louis, MO, USA), or fluorescein isothiocyanate (FITC;
green fluorescence) goat anti-rabbit (1:50; Sigma-Aldrich) were respectively used for visualization.
Immunofluorescence images were obtained with a confocal laser scanning microscope (Carl Zeiss
Japan, LSM 700 ZEN, Tokyo, Japan).
4.5. Immunohistochemical Analysis
Kir4.1 and GFAP expression in each brain region was analyzed with immunohistochemical
staining using the ABC method, as published previously [14,20,29]. After blocking, sections were
incubated with rabbit anti-Kir4.1 antibodies (1:100; Alomone Labs) or mouse anti-GFAP antibodies
(1:100; Progen) at 4 ◦C overnight. Thereafter, they were incubated with biotinylated goat anti-rabbit
IgG antibodies (1:400, Vector Laboratories, Burlingame, CA, USA) or biotinylated goat anti-mouse
IgG antibodies (1:400, Sigma-Aldrich) for 60 min and with avidin-biotinylated horseradish peroxidase
complexes (Vectastain ABC Kit, Vector Laboratories) for an additional 60 min. Kir4.1-IR and GFAP-IR
were visualized by the diaminobenzidine-nickel staining method.
Kir4.1 and GFAP expression were quantified by counting the number of Kir4.1-IR-positive or
GFAP-IR-positive cells in a 350 × 350 µm2 grid laid over each region of the brain, as shown in
Figure 2B, which included the following regions: medial parietal association cortex (MPtA), primary
somatosensory cortex barrel field (S1BF), primary auditory cortex (Au1), perirhinal cortex (PRh),
piriform cortex (Pir), hippocampal CA1, CA2, CA3, and dentate gyrus (DG), medial amygdaloid
nucleus posteroventral part (MePV), medial amygdaloid nucleus posterodorsal part (MePD),
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posteromedial cortical amygdaloid nucleus (PMCo), basomedial amygdaloid nucleus posterior part
(BMP), basolateral amygdaloid nucleus posterior part (BLP), lateral amygdaloid nucleus ventromedial
part (LaVM), lateral habenula (LHb), ventromedial thalamus (VM), posterior hypothalamus (PH),
dorsomedial hypothalamic nucleus, and dorsal part (DMD). The Kir4.1 expression was expressed as a
percentage of the number of Kir4.1-IR-positive cells relative to that of GFAP-IR-positive cells obtained
from successive slices of the same animals.
4.6. Drug Treatments
To determine whether an antiepileptic agent modified the pathophysiological alterations in Kir4.1
channels in Lgi1-related epileptogenesis, we studied the prophylactic actions of VPA in Lgi1 mutant rats,
with a focus on its regulation of Kir4.1 channel expression. From one day before priming stimulation,
animals were intraperitoneally injected with VPA (30 mg/kg and 200 mg/kg) (Sigma-Aldrich) or
saline for 14 continuous days (Figure 6). Then, the animals were subjected to the audiogenic seizure
test four weeks after the last VPA treatment, and brain samples were obtained as described previously.
4.7. Statistical Analysis
All of the data were expressed as the mean ± S.E.M. Comparisons between two groups
(expressional changes of Kir4.1 determined by immunohistochemical analysis in each region) were
performed by a parametric Student’s t-test. Statistical significance of differences among multiple
groups (expressional changes of Kir4.1 or GFAP determined by immunohistochemical analysis in each
region) was determined by one-way ANOVA followed by Tukey’s post hoc test. A p-value of less than
0.05 was considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/5/
1013/s1.
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